{"disease":{"id":"anemia-due-to-chemotherapy","name":"Anemia due to chemotherapy","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":6,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"retacrit","indication_name":"Anemia due to chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epogen","generic_name":"Epoetin Alfa-Epbx","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating agent (ESA)","quality_score":10,"revenue":"400","mechanism":"Epoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin."},{"drug_id":"epoetin-alfa","indication_name":"Anemia due to chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epogen","generic_name":"EPOETIN ALFA","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating Agent","quality_score":63,"revenue":"400","mechanism":"Epogen works by binding to the erythropoietin receptor, triggering a cascade of signals that stimulate the production of red blood cells."},{"drug_id":"darbepoetin-alfa","indication_name":"Anemia due to and following chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aranesp","generic_name":"DARBEPOETIN ALFA","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating Agent [EPC]","quality_score":10,"revenue":"400","mechanism":"Aranesp works by binding to the erythropoietin receptor, mimicking the action of natural erythropoietin to stimulate red blood cell production."},{"drug_id":"aranesp","indication_name":"Anemia due to and following chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aranesp","company_name":"University of Washington","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"erythropoietin","indication_name":"Anemia due to chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erythropoietin","company_name":"Nanjing First Hospital, Nanjing Medical University","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":null},{"drug_id":"epoetin-beta","indication_name":"Anemia due to chemotherapy for nonmyeloid cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neorecormon","generic_name":"EPOETIN BETA","company_name":"Roche Registration Limited","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Neorecormon works by binding to the erythropoietin receptor, mimicking the action of natural erythropoietin to stimulate red blood cell production."},{"drug_id":"darbepoetin","indication_name":"Anemia due to and following chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Darbepoetin","company_name":"NICHD Neonatal Research Network","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"epoetin-theta","indication_name":"Anemia due to chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eporatio","generic_name":"EPOETIN THETA","company_name":"","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"neorecormon","indication_name":"Anemia due to chemotherapy for nonmyeloid cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neorecormon","company_name":"Centre Hospitalier Universitaire, Amiens","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"epogen","indication_name":"Anemia due to chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epogen","company_name":"Johns Hopkins University","drug_phase":"discontinued","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"procrit","indication_name":"Anemia due to chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Procrit","company_name":"University of Louisville","drug_phase":"discontinued","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":11,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"retacrit","guideline_body":"FDA label","recommendation":"RETACRIT is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.","line_of_therapy":"adjunctive","evidence_grade":"not specified","guideline_year":null},{"drug_id":"retacrit","guideline_body":"FDA label","recommendation":"RETACRIT is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}